Grab your ticket

Online Live Stream Features

All sessions of this unique course online

Live interaction options between the delegates and trainer

Available via mobile, tablet or laptop

Reveal the full schedule, program, and trainer info!

Download the brochure and reveal the full program details

Meet the training leader

  • Dr. Tina Amini
  • Medical Device Division Director
  • NDA Group AB, United Kingdom
Learn more

Course description

As delivery system technology and medical devices continue to develop, the combination of drug-device and device-drug modalities are rapidly increasing and the distinction between the modalities is becoming blurred. In some situations, it is difficult to determine as to which regulations, submission procedure and pathway to market must be followed. Correct classification is a key as in the European Union, combination products are regulated as either medicinal products or medical devices.

This course will cover the definition of combination products, EU regulatory pathways, and will explain the current state of developments as medical device manufacturers and marketing authorisation holders prepare for the new requirements.

Key topics

Key considerations for Combinations regulated as a medicinal product

EU market access for devices with an ancillary medicinal substance

EU MDR key changes and its impact on Drug Device Combination Products

Case study on combination products regulated as medical devices

Labelling requirements for drug device combination products

Life cycle management

Post-market surveillance for combination products

Key takeaways

Medtech and Pharmaceutical/biotech companies increasingly must stay informed about implications of the EU MDR. EU MDR came into full effect on 26 May 2021 and will encompass all integral, single-use combination products regulated as medicinal products. In the European Union, combination products are regulated as either medicinal products or medical devices.

For marketed CE Marked devices under MDD and AIMDD whether standalone or co-packaged with medicinal products, these devices must also conform to MDR.

“Substantial” device design changes of already marketed single integral combination products will require NB opinion. To ensure that operations conform with the EU MDR, pharmaceutical/biotech companies must have compliant design controls, integrated risk-management procedures, and improved processes for complaint handling. Companies must have closer oversight of their device and component manufacturers. Because compliance is an ongoing activity that lasts throughout a device’s product lifecycle, businesses are encouraged to incorporate device compliance processes into their operations as soon as possible. Given overdemand for notified bodies in the regulatory arena, an early start can make the difference between a product market freeze and full compliance for market access.


Delegate Fee

from 1396 € Buy


Based on your specific needs and goals, we will build a training program that will equip your employees with the right set of skills and practical knowledge to achieve your organization's targets.

Request in-house training

Sneak peek into the program

Get the complete program line-up, speaker details and more.

Download brochure

Fill in details below to download your PDF brochure.

Contact us